Evidence map›Paper›PMID 42552173›Full record

ArticleTrends in molecular medicine2026

Scleroderma: disease subtypes and multiorgan manifestations.

Nathan M Johnson, Monique E Hinchcliff, Ian D Odell

Abstract read
In one paragraph

Article in Trends in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nathan M JohnsonDepartment of Internal Medicine, Section of Rheumatology, Allergy & Immunology, Yale University School of Medicine, New Haven, CT, USA.
Monique E HinchcliffDepartment of Internal Medicine, Section of Rheumatology, Allergy & Immunology, Yale University School of Medicine, New Haven, CT, USA.
Ian D OdellDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: ian.odell@yale.edu.

Funding

TRAINING PROGRAM IN INVESTIGATIVE RHEUMATOLOGYT32AR007107 · NIAMS · YALE UNIVERSITY · PI RICHARD J BUCALA · 1986 to 2026
$7.5M
Epidermal Growth Factor Receptor Signaling in Fibrotic Skin DiseaseK08AR077689 · NIAMS · YALE UNIVERSITY · PI ODELL, IAN D · 2021 to 2025
$861k
Validating Novel Outcomes to Enable Systemic Sclerosis Calcinosis Cutis Clinical TrialsR01AR085316 · NIAMS · YALE UNIVERSITY · PI MONIQUE Evangeline HINCHCLIFF · 2025 to 2026
$487k
Interrogation of T cell Bystander Activation in SclerodermaR03AR083454 · NIAMS · YALE UNIVERSITY · PI ODELL, IAN D · 2024 to 2024
$147k
NIAMS NIH HHS K08 AR077689NIAMS NIH HHS R01 AR085316NIAMS NIH HHS R03 AR083454NIAMS NIH HHS T32 AR007107
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42552173
PMCPMC13527773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.